ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This finding agrees with the previous study which reported that using combination therapy, such as ABT-199 and IM that targets both BCL-2 and BCR-ABL tyrosine kinase, has a significant impact on regulating and improving CML patient stability in chronic phase and blast crisis phases [25].